Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anaptysbio (ANAB) EPS (Weighted Average and Diluted) (2016 - 2025)

Anaptysbio filings provide 9 years of EPS (Weighted Average and Diluted) readings, the most recent being $1.7 for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 357.58% year-over-year to $1.7, compared with a TTM value of -$0.4 through Dec 2025, up 92.23%, and an annual FY2025 reading of -$0.46, up 91.02% over the prior year.
  • EPS (Weighted Average and Diluted) hit $1.7 in Q4 2025 for Anaptysbio, up from $0.52 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $1.7 in Q4 2025, with the low at -$1.71 in Q2 2024.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$1.18 (2021), compared with a mean of -$0.92.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 5650.0% in 2022, then surged 357.58% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$1.19 in 2021, then grew by 21.85% to -$0.93 in 2022, then tumbled by 70.97% to -$1.59 in 2023, then skyrocketed by 58.49% to -$0.66 in 2024, then surged by 357.58% to $1.7 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at $1.7, $0.52, and -$1.34 for Q4 2025, Q3 2025, and Q2 2025 respectively.